Clinical implications of fluvoxamine and fluoxetine with sigma-1 receptor chaperone activity in the treatment of neuropsychiatric disorders

Basit Öğe Kaydı
dc.authorscopusid29067508300
dc.authorscopusid55365316700
dc.contributor.authorAlbayrak, Yakup
dc.contributor.authorHashimoto, Kenji
dc.date.accessioned2022-05-11T14:41:05Z
dc.date.available2022-05-11T14:41:05Z
dc.date.issued2015
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractSelective serotonin reuptake inhibitors (SSRIs) are used as therapeutic drugs for a number of neuropsychiatric diseases throughout the world. Although all SSRIs act by blockading serotonin transporters, leading to elevated serotonin levels in the central nervous system (CNS), it is well known that their pharmacology is quite heterogeneous. Endoplasmic reticulum protein sigma-1 receptors represent a unique chaperone activity, and they exert a potent influence on a number of neurotransmitter systems. Accumulating evidence suggests that sigma-1 receptors play a role in the pathophysiology of neuropsychiatric and cardiovasular diseases, as well as in the mechanisms of some SSRIs. Among the SSRIs, the order of affinity for sigma-1 receptors is as follows: fluvoxamine > sertraline > fluoxetine > escitalopram > citalopram » paroxetine. In cell culture systems, some SSRIs (e.g., fluvoxamine, fluoxetine and escitalopram) potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and these effects can be antagonized by the selective sigma-1 receptor antagonist, NE-100. Furthermore, fluvoxamine, but not paroxetine or sertraline, improved phencyclidine-induced cognitive impairment in mice, and again, this effect could be antagonized by NE-100. Several clinical studies have found that fluvoxamine may offer beneficial effects in patients with neuropsychiatric disorders. In this chapter, the authors will discuss the role of sigma-1 receptors in the mechanistic action of some SSRIs and new clinical implications for SSRIs with potent sigma-1 receptor chaperone activity. © 2015 by Nova Science Publishers, Inc. All rights reserved.
dc.identifier.endpage293
dc.identifier.isbn9781634820776
dc.identifier.isbn9781634820769
dc.identifier.scopus2-s2.0-84956514249
dc.identifier.startpage279
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9055
dc.indekslendigikaynakScopus
dc.institutionauthorAlbayrak, Yakup
dc.language.isoen
dc.publisherNova Science Publishers, Inc.
dc.relation.ispartofFluoxetine: Pharmacology, Mechanisms of Action and Potential Side Effects
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCognition
dc.subjectNeurite outgrowth
dc.subjectNeuroplasticity
dc.subjectNeuroprotection
dc.subjectSelective serotonin reuptake inhibitors (SSRIs)
dc.subjectSigma-1 receptor chaperone
dc.titleClinical implications of fluvoxamine and fluoxetine with sigma-1 receptor chaperone activity in the treatment of neuropsychiatric disorders
dc.typeBook Chapter

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu